Tempol (Sigma-Aldrich Chemical Company, St. Louis, MO, USA) was prepared and dissolved daily in distilled water in a concentration of 0.4 g/20 mL. The choice of Tempol dose was on a pilot trial (Supplementary Materials ) guided by previously published studies to figure out the appropriate method of administration [40 (link),58 (link),59 (link),60 (link)], and the applicable duration of treatment [31 (link),42 (link),44 (link),56 (link),61 (link)].
In this study, we did not compare with a pharmacological control since the existing approved pharmacological treatments for OA are limited for the relief of OA symptoms (e.g., NSAIDs and corticosteroids), and there is a lack of licensed disease-modifying osteoarthritis drugs (DMOADs) that could slow the narrowing of joint space and provide symptomatic relief.
In this study, we did not compare with a pharmacological control since the existing approved pharmacological treatments for OA are limited for the relief of OA symptoms (e.g., NSAIDs and corticosteroids), and there is a lack of licensed disease-modifying osteoarthritis drugs (DMOADs) that could slow the narrowing of joint space and provide symptomatic relief.
Free full text: Click here
